Business Context and Reporting Period
This Form 8-K Current Report was filed by Zimmer Holdings, Inc. on March 10, 2015. The filing primarily announces the entry into a material definitive agreement for a public offering of senior notes. The report also references ongoing merger activities involving LVB Acquisition, Inc. and Biomet, Inc., noting that a registration statement on Form S-4 was declared effective on September 29, 2014.
Key Financial Metrics and Debt Issuance
The Company entered into an underwriting agreement to issue a total of $7.65 billion in aggregate principal amount of senior notes across seven tranches. The filing does not provide current revenue, profit, cash flow, or margin data, as this is a transactional report rather than a periodic financial statement.
| Note Series | Principal Amount | Coupon Rate | Maturity Date |
|---|---|---|---|
| 2017 Notes | $500,000,000 | 1.450% | April 1, 2017 |
| 2018 Notes | $1,150,000,000 | 2.000% | April 1, 2018 |
| 2020 Notes | $1,500,000,000 | 2.700% | April 1, 2020 |
| 2022 Notes | $750,000,000 | 3.150% | April 1, 2022 |
| 2025 Notes | $2,000,000,000 | 3.550% | April 1, 2025 |
| 2035 Notes | $500,000,000 | 4.250% | August 15, 2035 |
| 2045 Notes | $1,250,000,000 | 4.450% | August 15, 2045 |
Interest payments for the 2017 through 2025 notes are payable semi-annually on April 1 and October 1, commencing October 1, 2015. Interest for the 2035 and 2045 notes is payable semi-annually on February 15 and August 15, commencing August 15, 2015.
Material Changes and Transaction Details
The primary material change is the execution of the Underwriting Agreement with Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC, and Merrill Lynch, Pierce, Fenner & Smith Incorporated. The sale of the notes is scheduled to close on March 19, 2015, subject to customary closing conditions. The notes are issued pursuant to a third supplemental indenture dated November 17, 2009.
Guidance, Outlook, and Risks
The filing includes unaudited pro forma condensed combined financial information (Exhibit 99.1) reflecting the terms of the new notes. Management includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. The filing highlights that certain executive officers and directors of LVB have interests in the proposed merger that may differ from general stockholders, including retention and severance benefits. The document explicitly states it does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the closing of the $7.65 billion note offering on or around March 19, 2015.
- Review the unaudited pro forma condensed combined financial information in Exhibit 99.1 to assess the impact of the new debt on the Company's leverage.
- Confirm the status of the merger between Zimmer Holdings, Inc. and LVB Acquisition, Inc. (parent of Biomet, Inc.) by reviewing the Form S-4 filed on September 29, 2014.
- Monitor the Company's liquidity position given the significant increase in debt obligations.